As 22,000 participants prepare to descend on Chicago next month for the American Association for Cancer Research (AACR) 2018 meeting, the organization released many of the abstracts for presentations. Unfortunately, as Evercore ISI analyst Umer Raffat wrote in a note to clients, "Most abstracts of significance are all embargoed."
A new report by strategy and marketing consultants Simon-Kucher & Partners found that drug companies that involve their pricing and market access (P&MA) teams early in the development of drugs appear to be the most profitable.
Going after neurodegenerative diseases where lysosomal dysfunction is an underlying cause, Prevail Therapeutics Inc. announced a $75 million series A round to fund development of its gene therapies.
Blockchain, the transaction-following technology that got its fame as a way to follow the movements of cryptocurrencies such as Bitcoin, is making its way into the pharmaceutical industry, proving its potential uses are far-flung.
Blockchain, the transaction-following technology that got its fame as a way to follow the movements of cryptocurrencies such as Bitcoin, is making its way into the pharmaceutical industry, proving its potential uses are far-flung.
Despite being the second most prevalent mental disorder with a third of the general population reporting insomnia complaints and 10 percent meeting the strict definition of insomnia disorder, the treatment options for the disease are lacking. Considering that many treatments lead to tolerance and dependence and the potential for morning sedation, drugs using new mechanisms of action are sorely needed.
After a drought of nearly a decade without an FDA approval, the market for hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults, is heating up.
Oral mucositis, painful sores that form in the mouths of many cancer patients, are more than just an annoying side effect of radiation and chemotherapy treatments. When they reach grade 3, patients can no longer eat solid foods, and at grade 4 patients can no longer even drink, often resulting in the stopping of cancer treatments.
In what seems to be an eternally growing partnership, Regeneron Pharmaceuticals Inc. and Sanofi SA plan to accelerate development of two drugs already partnered under their multidrug agreements.
